denkapparat Operations GmbH Invests $1.14 Million in Gilead Sciences, Inc. (NASDAQ:GILD)

denkapparat Operations GmbH bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,142,000. Gilead Sciences makes up about 1.7% of denkapparat Operations GmbH’s portfolio, making the stock its 7th biggest position.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Premier Fund Managers Ltd lifted its stake in shares of Gilead Sciences by 46.7% in the 4th quarter. Premier Fund Managers Ltd now owns 15,710 shares of the biopharmaceutical company’s stock valued at $1,445,000 after acquiring an additional 5,000 shares during the last quarter. Orion Portfolio Solutions LLC raised its position in Gilead Sciences by 3.7% in the fourth quarter. Orion Portfolio Solutions LLC now owns 90,026 shares of the biopharmaceutical company’s stock valued at $8,316,000 after purchasing an additional 3,224 shares during the last quarter. New Age Alpha Advisors LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth about $10,778,000. Kiltearn Partners LLP increased its stake in shares of Gilead Sciences by 107.9% in the fourth quarter. Kiltearn Partners LLP now owns 150,900 shares of the biopharmaceutical company’s stock valued at $13,939,000 after buying an additional 78,300 shares during the period. Finally, Norges Bank bought a new position in Gilead Sciences in the 4th quarter valued at approximately $1,789,254,000. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on GILD. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Oppenheimer raised their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $105.12.

Gilead Sciences Stock Up 1.7 %

GILD stock opened at $111.16 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a market capitalization of $138.43 billion, a price-to-earnings ratio of 300.43, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The business’s 50 day moving average price is $105.08 and its two-hundred day moving average price is $94.58. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.